Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$27.21 CAD
Change Today -1.79 / -6.17%
Volume 23.8K
TR On Other Exchanges
As of 4:10 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

trillium therapeutics inc (TR) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/13/15 - C$37.27
52 Week Low
10/17/14 - C$6.15
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

trillium therapeutics inc (TR) Related Businessweek News

No Related Businessweek News Found

trillium therapeutics inc (TR) Details

Trillium Therapeutics Inc., an immuno-oncology company, develops therapies for the treatment of cancer. Its primary program is SIRPaFc, an antibody-like fusion protein, which blocks the activity of CD47, a molecule that allows tumor cells to escape destruction by the immune system. The company also develops CD200 mAb, a human monoclonal antibody that blocks the activity of CD200, an immunosuppressive molecule that is overexpressed by various hematopoietic and solid tumors. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Toronto, Canada.

20 Employees
Last Reported Date: 05/13/15
Founded in 2004

trillium therapeutics inc (TR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$390.0K
Chief Financial Officer
Total Annual Compensation: C$218.8K
Vice President of Drug Development
Total Annual Compensation: C$205.0K
Chief Scientific Officer
Total Annual Compensation: C$270.0K
Compensation as of Fiscal Year 2014.

trillium therapeutics inc (TR) Key Developments

Trillium Therapeutics Inc. Reports Unaudited Consolidated Earnings Results for First Third Quarter Ended March 31, 2015

Trillium Therapeutics Inc. reported unaudited consolidated earnings results for first third quarter ended March 31, 2015. For the quarter, the company reported net loss and comprehensive loss of CAD 4,670,313 or CAD 0.98 per basic and diluted common share compared to CAD 2,040,060 or CAD 0.50 per basic and diluted common share a year ago. Finance loss was CAD 70,741 compared to CAD 108,592 a year ago. Cash used in operating activities was CAD 4,612,249 compared to CAD 1,509,541 a year ago. Purchase of property and equipment was CAD 82,814 compared to CAD 10,091 a year ago.

Trillium Therapeutics Inc., Annual General Meeting, May 27, 2015

Trillium Therapeutics Inc., Annual General Meeting, May 27, 2015., at 15:00 US Eastern Standard Time. Location: at the offices of the Corporation at 96 Skyway Avenue. Agenda: To receive the audited consolidated financial statements of the Corporation for the year ended December 31, 2014, together with the auditors' report thereon; to elect directors of the Corporation for the ensuing year; to reappoint Ernst & Young, LLP, Chartered Professional Accountants, Licensed Public Accountants, as auditors of the Corporation for the ensuing year and to authorize the directors to fix the remuneration to be paid to the auditors; and to transact such other business as may properly come before the Meeting or any adjournment or postponement thereof.

Trillium Therapeutics Inc. Announces Providing of Update on its SIRPaFc Immune Checkpoint Inhibitor Program

Trillium Therapeutics Inc. announced that it will be providing an update on its SIRPaFc immune checkpoint inhibitor program, targeting the CD47 protein, at the 106 Annual Meeting of the American Association for Cancer Research. The meeting will be held April 18-22, 2015 in Philadelphia, PA. Details of the poster presentation, entitled Lack of CD47 membrane mobility contributes to the poor erythrocyte binding of SIRP Fc, a novel CD47-blocking cancer immunotherapeutic. The company will present data from an expanded pool of donors that conclusively demonstrate that its SIRPaFc fusion protein, which targets the CD47 do not eat signal, binds very poorly to human red blood cells (RBCs) despite high expression of the CD47 target and strong reactivity with anti-CD47 monoclonal antibodies. This poor binding is independent of gender, ABO or Rh blood groups. SIRPaFc, however, binds RBCs from other species, including non-human primates, and induces clinically significant anemia in monkeys after intravenous administration. Biochemical analysis reveals that the failure of SIRPaFc to bind RBCs correlates with the presence of detergent-insoluble CD47 in RBC membranes, which is consistent with a model in which CD47 mobility is required to form high affinity clusters with SIRPaFc. These results expand upon its preliminary data presented at last year's AACR meeting and provide a mechanistic understanding of the unique species selectivity of this poor RBC binding phenomenon. The company's cynomologus monkey data indicate that targeting CD47 with an agent that can bind to RBCs may have adverse clinical consequences.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TR:CN C$27.21 CAD -1.79

TR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TR.
View Industry Companies

Industry Analysis


Industry Average

Valuation TR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 10.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TRILLIUM THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at